tiprankstipranks
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
US Market

Aardvark Therapeutics, Inc. (AARD) Stock Forecast & Price Target

151 Followers
See the Price Targets and Ratings of:

AARD Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
5 Buy
4 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Aardvark
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AARD Stock 12 Month Forecast

Average Price Target

$13.26
▲(208.34% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Aardvark Therapeutics, Inc. in the last 3 months. The average price target is $13.26 with a high forecast of $45.00 and a low forecast of $4.07. The average price target represents a 208.34% change from the last price of $4.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","46":"$46","13.75":"$13.75","24.5":"$24.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.25875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.07</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,13.75,24.5,35.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.09,7.236923076923077,10.383846153846154,13.530769230769229,16.677692307692304,19.824615384615385,22.971538461538458,26.118461538461535,29.265384615384612,32.41230769230769,35.559230769230766,38.70615384615384,41.85307692307691,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.09,4.795288461538461,5.500576923076923,6.205865384615384,6.911153846153846,7.616442307692307,8.321730769230768,9.02701923076923,9.732307692307693,10.437596153846153,11.142884615384615,11.848173076923075,12.553461538461537,{"y":13.25875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.09,4.088461538461538,4.086923076923076,4.085384615384616,4.083846153846154,4.082307692307692,4.0807692307692305,4.07923076923077,4.077692307692308,4.076153846153846,4.0746153846153845,4.073076923076924,4.071538461538462,{"y":4.07,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$13.26Lowest Price Target$4.07
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$9
Buy
109.30%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Incyte (NASDAQ: INCY)
William Blair Analyst forecast on AARD
William Blair
William Blair
$4.07
Buy
-5.35%
Downside
Reiterated
03/24/26
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
RBC Capital Analyst forecast on AARD
RBC Capital
RBC Capital
$6
Hold
39.53%
Upside
Reiterated
03/23/26
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
B. Riley Securities Analyst forecast on AARD
B. Riley Securities
B. Riley Securities
$32$8
Buy
86.05%
Upside
Assigned
03/23/26
Aardvark Therapeutics price target lowered to $8 from $32 at B. RileyAardvark Therapeutics price target lowered to $8 from $32 at B. Riley
Morgan Stanley Analyst forecast on AARD
Morgan Stanley
Morgan Stanley
$7
Hold
62.79%
Upside
Reiterated
03/23/26
Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (Other OTC: SEMHF), Immatics (NASDAQ: IMTX) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)
H.C. Wainwright Analyst forecast on AARD
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
03/02/26
Aardvark Therapeutics downgraded to Neutral from Buy at H.C. WainwrightAardvark Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Cantor Fitzgerald Analyst forecast on AARD
Cantor Fitzgerald
Cantor Fitzgerald
$50$45
Buy
946.51%
Upside
Reiterated
03/02/26
Aardvark Therapeutics price target lowered to $45 from $50 at Cantor FitzgeraldAardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on AARD
Stifel Nicolaus
Stifel Nicolaus
$24$6
Hold
39.53%
Upside
Downgraded
03/02/26
Aardvark Therapeutics downgraded to Hold from Buy at StifelAardvark Therapeutics downgraded to Hold from Buy at Stifel
Oppenheimer Analyst forecast on AARD
Oppenheimer
Oppenheimer
$35$21
Buy
388.37%
Upside
Reiterated
02/27/26
Aardvark Therapeutics price target lowered to $21 from $35 at OppenheimerAardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer
Bank of America Securities Analyst forecast on AARD
Bank of America Securities
Bank of America Securities
$25
Buy
481.40%
Upside
Reiterated
12/18/25
Bank of America Securities Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)
Raymond James Analyst forecast on AARD
Raymond James
Raymond James
$47
Buy
993.02%
Upside
Initiated
12/02/25
Aardvark Therapeutics, Inc. (AARD) Gets a Buy from Raymond James
JonesTrading Analyst forecast on AARD
JonesTrading
JonesTrading
$33
Buy
667.44%
Upside
Initiated
09/30/25
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$9
Buy
109.30%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK), Aardvark Therapeutics, Inc. (NASDAQ: AARD) and Incyte (NASDAQ: INCY)
William Blair Analyst forecast on AARD
William Blair
William Blair
$4.07
Buy
-5.35%
Downside
Reiterated
03/24/26
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
RBC Capital Analyst forecast on AARD
RBC Capital
RBC Capital
$6
Hold
39.53%
Upside
Reiterated
03/23/26
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
B. Riley Securities Analyst forecast on AARD
B. Riley Securities
B. Riley Securities
$32$8
Buy
86.05%
Upside
Assigned
03/23/26
Aardvark Therapeutics price target lowered to $8 from $32 at B. RileyAardvark Therapeutics price target lowered to $8 from $32 at B. Riley
Morgan Stanley Analyst forecast on AARD
Morgan Stanley
Morgan Stanley
$7
Hold
62.79%
Upside
Reiterated
03/23/26
Analysts Conflicted on These Healthcare Names: Siemens Healthineers AG (Other OTC: SEMHF), Immatics (NASDAQ: IMTX) and Aardvark Therapeutics, Inc. (NASDAQ: AARD)
H.C. Wainwright Analyst forecast on AARD
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
03/02/26
Aardvark Therapeutics downgraded to Neutral from Buy at H.C. WainwrightAardvark Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Cantor Fitzgerald Analyst forecast on AARD
Cantor Fitzgerald
Cantor Fitzgerald
$50$45
Buy
946.51%
Upside
Reiterated
03/02/26
Aardvark Therapeutics price target lowered to $45 from $50 at Cantor FitzgeraldAardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on AARD
Stifel Nicolaus
Stifel Nicolaus
$24$6
Hold
39.53%
Upside
Downgraded
03/02/26
Aardvark Therapeutics downgraded to Hold from Buy at StifelAardvark Therapeutics downgraded to Hold from Buy at Stifel
Oppenheimer Analyst forecast on AARD
Oppenheimer
Oppenheimer
$35$21
Buy
388.37%
Upside
Reiterated
02/27/26
Aardvark Therapeutics price target lowered to $21 from $35 at OppenheimerAardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer
Bank of America Securities Analyst forecast on AARD
Bank of America Securities
Bank of America Securities
$25
Buy
481.40%
Upside
Reiterated
12/18/25
Bank of America Securities Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)
Raymond James Analyst forecast on AARD
Raymond James
Raymond James
$47
Buy
993.02%
Upside
Initiated
12/02/25
Aardvark Therapeutics, Inc. (AARD) Gets a Buy from Raymond James
JonesTrading Analyst forecast on AARD
JonesTrading
JonesTrading
$33
Buy
667.44%
Upside
Initiated
09/30/25
Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aardvark Therapeutics, Inc.

3 Months
xxx
Success Rate
4/6 ratings generated profit
67%
Average Return
+7.17%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +7.17% per trade.
1 Year
Joshua SchimmerCantor Fitzgerald
Success Rate
0/5 ratings generated profit
0%
Average Return
-38.56%
Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.56% per trade.
2 Years
xxx
Success Rate
0/5 ratings generated profit
0%
Average Return
-39.92%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -39.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AARD Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
14
16
11
9
7
Buy
1
1
1
2
2
Hold
0
0
0
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
17
12
17
15
In the current month, AARD has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. AARD average Analyst price target in the past 3 months is 13.26.
Each month's total comprises the sum of three months' worth of ratings.

AARD Financial Forecast

AARD Earnings Forecast

Next quarter’s earnings estimate for AARD is -$0.83 with a range of -$1.00 to -$0.70. The previous quarter’s EPS was -$0.75. AARD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year AARD has its overall industry.
Next quarter’s earnings estimate for AARD is -$0.83 with a range of -$1.00 to -$0.70. The previous quarter’s EPS was -$0.75. AARD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year AARD has its overall industry.
No data currently available

AARD Sales Forecast

Next quarter’s sales forecast for AARD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AARD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year AARD has its overall industry.
Next quarter’s sales forecast for AARD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AARD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year AARD has its overall industry.

AARD Stock Forecast FAQ

What is AARD’s average 12-month price target, according to analysts?
Based on analyst ratings, Aardvark Therapeutics, Inc.’s 12-month average price target is 13.26.
    What is AARD’s upside potential, based on the analysts’ average price target?
    Aardvark Therapeutics, Inc. has 208.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AARD a Buy, Sell or Hold?
          Aardvark Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Aardvark Therapeutics, Inc.’s price target?
            The average price target for Aardvark Therapeutics, Inc. is 13.26. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $4.07. The average price target represents 208.34% Increase from the current price of $4.3.
              What do analysts say about Aardvark Therapeutics, Inc.?
              Aardvark Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of AARD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.